According to current knowledge, RUNX2 acts as an oncogene and is related to the more aggressive forms of the disease, whereas RUNX3 exerts a tumour-suppressive role and could be used as a biomarker for early HCC detection. This evidence concerns the gene RUNX2 and neoplasm.